Abstract:BACKGROUND:Oxaliplatin is one of the most commonly used chemotherapeutic agent for the treatment of various cancers, including gastric cancer. It has, however, a narrow therapeutic index due to its toxicity and the occurrence of drug resistance. Hence, it is of great significance to develop novel therapies to potentiate the anti-tumor effect and reduce the toxicity of oxaliplatin. In our previous study, we demonstrated that ethaselen (BBSKE), an inhibitor of thioredoxin reductase, effectively inhibited the growth of gastric cancer cells and promoted apoptosis in vitro. In the present study, we investigated whether BBSKE can potentiate the anti-tumor effect of oxaliplatin in gastric cancer in vivo and vitro.METHODS:Cellular apoptosis and ROS levels were analyzed by flow cytometry. Thioredoxin reductase 1 (TrxR1) activity in gastric cancer cells, organoid and tumor tissues was determined by using the endpoint insulin reduction assay. Western blot was used to analyze the expressions of the indicated proteins. Nude mice xenograft models were used to test the effects of BBSKE and oxaliplatin combinations on gastric cancer cell growth in vivo. In addition, we also used the combined treatment of BBSKE and oxaliplatin in three cases of gastric cancer Patient-Derived organoid (GC-PDO) to detect the anti-tumor effect.RESULTS:We found that BBSKE significantly enhanced oxaliplatin-induced growth inhibition in gastric cancer cells by inhibiting TrxR1 activity. Because of the inhibition of TrxR1 activity, BBSKE synergized with oxaliplatin to enhance the production of ROS and activate p38 and JNK signaling pathways which eventually induced apoptosis of gastric cancer cells. In vivo, we also found that BBSKE synergized with oxaliplatin to suppress the gastric cancer tumor growth in xenograft nude mice model, accompanied by the reduced TrxR1 activity. Remarkably, we found that BBSKE attenuated body weight loss evoked by oxaliplatin treatment. We also used three cases of GC-PDO and found that the combined treatment of BBSKE and oxaliplatin dramatically inhibited the growth and viability of GC-PDO with increased ROS level, decreased TrxR1 activity and enhanced apoptosis.CONCLUSIONS:This study elucidates the underlying mechanisms of synergistic effect of BBSKE and oxaliplatin, and suggests that the combined treatment has potential value in gastric cancer therapy.

Thioredoxin Reductase Inhibitor Ethaselen Inhibits Cancer Metastasis

The Antimetastatic Effect and Underlying Mechanisms of Thioredoxin Reductase Inhibitor Ethaselen.

A Novel Thioredoxin Reductase Inhibitor Inhibits Cell Growth and Induces Apoptosis in HL-60 and K562 Cells

Selenium-containing Thioredoxin Reductase Inhibitor Ethaselen Sensitizes Non-Small Cell Lung Cancer to Radiotherapy

Novel Mechanism of Ethaselen in Poorly Differentiated Colorectal RKO Cell Growth Inhibition: Simultaneous Regulation of TrxR Transcription, Expression and Enzyme Activity.

Bexarotene: a Promising Anticancer Agent

Dose-biomarker-response Modeling of the Anticancer Effect of Ethaselen in a Human Non-Small Cell Lung Cancer Xenograft Mouse Model

Ethaselen Synergizes with Oxaliplatin in Tumor Growth Inhibition by Inducing ROS Production and Inhibiting TrxR1 Activity in Gastric Cancer

Novel Thioredoxin Reductase Inhibitor Butaselen Inhibits Tumorigenesis by Down-Regulating Programmed Death-Ligand 1 Expression

Synergism Between Thioredoxin Reductase Inhibitor Ethaselen and Sodium Selenite in Inhibiting Proliferation and Inducing Death of Human Non-Small Cell Lung Cancer Cells.

Ethaselen: a potent mammalian thioredoxin reductase 1 inhibitor and novel organoselenium anticancer agent.

A Novel Organoselenium Compound Induces Cell Cycle Arrest and Apoptosis in Prostate Cancer Cell Lines.

Synergistic Inhibition of Sunitinib and Ethaselen Against Human Colorectal Cancer Cells Proliferation.

A thioredoxin reductase inhibitor induces growth inhibition and apoptosis in five cultured human carcinoma cell lines.

Butaselen Prevents Hepatocarcinogenesis and Progression Through Inhibiting Thioredoxin Reductase Activity

Thioredxin reductase inhibitor ethaselen increases the drug sensitivity of the colon cancer cell line LoVo towards cisplatin via regulation of G1 phase and reversal of G2/M phase arrest

Augmented antitumor effects of combination therapy of cisplatin with ethaselen as a novel thioredoxin reductase inhibitor on human A549 cell in vivo

The Inhibitory Effect of A Novel Organoselenium Compound Bbske on the Tongue Cancer Tca8113 in Vitro and in Vivo

Ethaselen: a Novel Organoselenium Anticancer Agent Targeting Thioredoxin Reductase 1 Reverses Cisplatin Resistance in Drug-Resistant K562 Cells by Inducing Apoptosis.

Role of Thioredoxin Reductase 1 in Dysplastic Transformation of Human Breast Epithelial Cells Triggered by Chronic Oxidative Stress

Natural Diterpenoid Eriocalyxin B Covalently Modifies Glutathione and Selectively Inhibits Thioredoxin Reductase Inducing Potent Oxidative Stress-Mediated Apoptosis in Colorectal Carcinoma RKO Cells.